(Total Views: 817)
Posted On: 12/06/2021 7:23:51 PM
Post# of 148902
I ran across an article today about the effects of even mild Covid cases on the brain. The article was published on 9/24/21, so this may have been discussed previously. You can see the entire article at this link:
https://theconversation.com/preliminary-resea...sts-166145
I will paste some excerpts below. I am posting this as a question for discussion: could Leronlimab help restore the lost grey matter, or is this a case of once lost, there is no way to get it back? If Leronlimab might help, this would be a win-win: opportunity for Leronlimab as well as opportunity to help those affected get back to pre-Covid normal. I think it is particularly interesting because the study showed that people who had been infected with COVID-19 showed a loss of brain volume even when the disease was not severe enough to require hospitalization. The research has not yet been peer reviewed.
With more than 18 months of the pandemic in the rearview mirror, researchers have been steadily gathering new and important insights into the effects of COVID-19 on the body and brain. These findings are raising concerns about the long-term impacts that the coronavirus might have on biological processes such as aging.
As a cognitive neuroscientist, my past research has focused on understanding how normal brain changes related to aging affect people’s ability to think and move – particularly in middle age and beyond. But as more evidence came in showing that COVID-19 could affect the body and brain for months or longer following infection, my research team became interested in exploring how it might also impact the natural process of aging.
In August 2021, a preliminary but large-scale study investigating brain changes in people who had experienced COVID-19 drew a great deal of attention within the neuroscience community.
In that study, researchers relied on an existing database called the UK Biobank, which contains brain imaging data from over 45,000 people in the U.K. going back to 2014. This means – crucially – that there was baseline data and brain imaging of all of those people from before the pandemic.
The research team analyzed the brain imaging data and then brought back those who had been diagnosed with COVID-19 for additional brain scans. They compared people who had experienced COVID-19 to participants who had not, carefully matching the groups based on age, sex, baseline test date and study location, as well as common risk factors for disease, such as health variables and socioeconomic status.
The team found marked differences in gray matter – which is made up of the cell bodies of neurons that process information in the brain – between those who had been infected with COVID-19 and those who had not. Specifically, the thickness of the gray matter tissue in brain regions known as the frontal and temporal lobes was reduced in the COVID-19 group, differing from the typical patterns seen in the group that hadn’t experienced COVID-19.
In the general population, it is normal to see some change in gray matter volume or thickness over time as people age, but the changes were larger than normal in those who had been infected with COVID-19.
Interestingly, when the researchers separated the individuals who had severe enough illness to require hospitalization, the results were the same as for those who had experienced milder COVID-19. That is, people who had been infected with COVID-19 showed a loss of brain volume even when the disease was not severe enough to require hospitalization.
Finally, researchers also investigated changes in performance on cognitive tasks and found that those who had contracted COVID-19 were slower in processing information, relative to those who had not.
While we have to be careful interpreting these findings as they await formal peer review, the large sample, pre- and post-illness data in the same people and careful matching with people who had not had COVID-19 have made this preliminary work particularly valuable.
Early on in the pandemic, one of the most common reports from those infected with COVID-19 was the loss of sense of taste and smell.
Strikingly, the brain regions that the U.K. researchers found to be impacted by COVID-19 are all linked to the olfactory bulb, a structure near the front of the brain that passes signals about smells from the nose to other brain regions. The olfactory bulb has connections to regions of the temporal lobe. We often talk about the temporal lobe in the context of aging and Alzheimer’s disease because it is where the hippocampus is located. The hippocampus is likely to play a key role in aging, given its involvement in memory and cognitive processes.
The sense of smell is also important to Alzheimer’s research, as some data has suggested that those at risk for the disease have a reduced sense of smell. While it is far too early to draw any conclusions about the long-term impacts of these COVID-related changes, investigating possible connections between COVID-19-related brain changes and memory is of great interest – particularly given the regions implicated and their importance in memory and Alzheimer’s disease.
These new findings bring about important yet unanswered questions: What do these brain changes following COVID-19 mean for the process and pace of aging? And, over time does the brain recover to some extent from viral infection?
https://theconversation.com/preliminary-resea...sts-166145
I will paste some excerpts below. I am posting this as a question for discussion: could Leronlimab help restore the lost grey matter, or is this a case of once lost, there is no way to get it back? If Leronlimab might help, this would be a win-win: opportunity for Leronlimab as well as opportunity to help those affected get back to pre-Covid normal. I think it is particularly interesting because the study showed that people who had been infected with COVID-19 showed a loss of brain volume even when the disease was not severe enough to require hospitalization. The research has not yet been peer reviewed.
With more than 18 months of the pandemic in the rearview mirror, researchers have been steadily gathering new and important insights into the effects of COVID-19 on the body and brain. These findings are raising concerns about the long-term impacts that the coronavirus might have on biological processes such as aging.
As a cognitive neuroscientist, my past research has focused on understanding how normal brain changes related to aging affect people’s ability to think and move – particularly in middle age and beyond. But as more evidence came in showing that COVID-19 could affect the body and brain for months or longer following infection, my research team became interested in exploring how it might also impact the natural process of aging.
In August 2021, a preliminary but large-scale study investigating brain changes in people who had experienced COVID-19 drew a great deal of attention within the neuroscience community.
In that study, researchers relied on an existing database called the UK Biobank, which contains brain imaging data from over 45,000 people in the U.K. going back to 2014. This means – crucially – that there was baseline data and brain imaging of all of those people from before the pandemic.
The research team analyzed the brain imaging data and then brought back those who had been diagnosed with COVID-19 for additional brain scans. They compared people who had experienced COVID-19 to participants who had not, carefully matching the groups based on age, sex, baseline test date and study location, as well as common risk factors for disease, such as health variables and socioeconomic status.
The team found marked differences in gray matter – which is made up of the cell bodies of neurons that process information in the brain – between those who had been infected with COVID-19 and those who had not. Specifically, the thickness of the gray matter tissue in brain regions known as the frontal and temporal lobes was reduced in the COVID-19 group, differing from the typical patterns seen in the group that hadn’t experienced COVID-19.
In the general population, it is normal to see some change in gray matter volume or thickness over time as people age, but the changes were larger than normal in those who had been infected with COVID-19.
Interestingly, when the researchers separated the individuals who had severe enough illness to require hospitalization, the results were the same as for those who had experienced milder COVID-19. That is, people who had been infected with COVID-19 showed a loss of brain volume even when the disease was not severe enough to require hospitalization.
Finally, researchers also investigated changes in performance on cognitive tasks and found that those who had contracted COVID-19 were slower in processing information, relative to those who had not.
While we have to be careful interpreting these findings as they await formal peer review, the large sample, pre- and post-illness data in the same people and careful matching with people who had not had COVID-19 have made this preliminary work particularly valuable.
Early on in the pandemic, one of the most common reports from those infected with COVID-19 was the loss of sense of taste and smell.
Strikingly, the brain regions that the U.K. researchers found to be impacted by COVID-19 are all linked to the olfactory bulb, a structure near the front of the brain that passes signals about smells from the nose to other brain regions. The olfactory bulb has connections to regions of the temporal lobe. We often talk about the temporal lobe in the context of aging and Alzheimer’s disease because it is where the hippocampus is located. The hippocampus is likely to play a key role in aging, given its involvement in memory and cognitive processes.
The sense of smell is also important to Alzheimer’s research, as some data has suggested that those at risk for the disease have a reduced sense of smell. While it is far too early to draw any conclusions about the long-term impacts of these COVID-related changes, investigating possible connections between COVID-19-related brain changes and memory is of great interest – particularly given the regions implicated and their importance in memory and Alzheimer’s disease.
These new findings bring about important yet unanswered questions: What do these brain changes following COVID-19 mean for the process and pace of aging? And, over time does the brain recover to some extent from viral infection?
(11)
(0)Scroll down for more posts ▼
